Cytokinetics, Incorporated (CYTK)

Cytokinetics announced inducement equity awards to new employees in November and December 2025, and January 2026. The company reported its third-quarter 2025 financial results, with revenue up 318.1% compared to the same quarter last year, and reported an EPS of ($1.54), beating analyst estimates. Cytokinetics issued $750.0 million in convertible senior notes due 2031 and received $100 million from a drawing on a Royalty Pharma Multi Tranche Term Loan. Regulatory reviews for aficamten are progressing in the U.S., E.U., and China, with a late-cycle meeting with the U.S. FDA scheduled for September 2025 ahead of a December 26, 2025 PDUFA date. The stock experienced a 52-week low of $29.31 and a 52-week high of $70.98, and as of February 2025, the stock value had decreased by 47.24% over the past year.

No specific information regarding demand seasonality for Cytokinetics, Inc.'s products and services was found in the provided search results.

Cytokinetics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors for diseases where muscle performance is compromised. The company operates in the biopharmaceutical sector and biotechnology industry, focusing on muscle biology-directed drug candidates for cardiovascular and neuromuscular diseases. Its major products include Aficamten (MYQORZO), Omecamtiv Mecarbil, CK-586, and CK-089.

Cytokinetics' headquarters are in South San Francisco, California. The company's stock is traded on the NASDAQ Global Markets under the symbol CYTK and is listed on several European exchanges. Cytokinetics holds commercialization rights for aficamten in China and certain neighboring regions through a deal with Ji Xing Pharmaceuticals.

Cytokinetics maintains a reputation rooted in its commitment to scientific innovation in muscle biology and its patient-centric mission. Positive results from the Phase 3 SEQUOIA-HCM clinical trial for aficamten bolstered the company's scientific standing. Ongoing regulatory reviews of aficamten in the U.S., E.U., and China contribute positively to its reputation. However, the company's reputation was also affected by regulatory and clinical setbacks for other late-stage potential medicines.

Cytokinetics has significant institutional ownership, with 97.38% of its shares held by institutions such as T. Rowe Price Investment Management, Inc., BlackRock, Inc., Fmr Llc, Vanguard Group Inc, Wellington Management Group Llp, and State Street Corp. Individual ownership stands at 0.99%. There has been significant insider selling of the company's stock in the past three months.